zurück

Burosumab (new indication, 50 M € limit exceeded: FGF23-related hypophosphatemia in tumor-induced osteomalacia)

Subject:

Active Sustance: Burosumab
Name: Crysvita®
Therapeutic area: Hypophosphatemia
Pharmaceutical company: Kyowa Kirin GmbH

Time table:

Start: 01.09.2022
Publication of assessment: 01.12.2022
End of public hearing: 22.12.2022
Final decision by G-BA: middle of February 2023

Comparative therapy:

Phosphate substitution